Publications (3)3.48 Total impact

  • Qin Ni · Xie Tian-Sheng · Li Min-Wei · Liu Ke-Zhou
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate the effect of combination therapy with peginterferon alfa-2a (Pegasys) +/- nucleos(t)ide analogues (NUC) and bicyclol in chronic hepatitis B with high ALT levels at baseline and during early treatment. Methods: CHB patients were treated with PEG-IFNalpha-2a for a minimum of 48 weeks. All patients were followed up for 26 weeks post-treatment. Patients with HBV DNA > or = 1 x 10(8) copies/ml were combined with NUC (adefovir or entecavir) treatment. Patients with ALT > 500 U/L at baseline or ALT > 300 U/L after first injection of PEG-IFNalpha-2a received bicyclol treatment for 1-2 months (treatment group). Patients with 2 x ULN < ALT < 300 U/L and ALT < 300 U/L during treatment were enrolled into PEG-IFNalpha-2a +/- NUC antiviral monotherapy (control group). Responses defined as HBV DNA < 1 x 10(3) copies/ml, normal serum ALT, and HBeAg/HBsAg loss and seroconversion were analyzed at 26 weeks post-treatment. Results: A total of 54 patients (44 HBeAg positive, 10 HBeAg negative) were divided into two groups according to combination of bicyclol: treatment group (n = 20)--those who received combinition therapy with PEG-IFNalpha-2a +/- NUC and bicyclol, and control group (n = 34)--those who were treated with PEG-IFNalpha-2a +/- NUC antiviral monotherapy. During the first month of treatment, ALT levels declined gradually in treatment group. At 26 weeks post-treatment, the rates of ALT normalization and HBV DNA below the limit of 1 x 10(3) copies/ml were similar in both groups. Six patients in treatment group achieved HBsAg seroconversion at 26 weeks post-treatment, whereas so did 4 patients of control group (30% vs. 11.8%, P = 0.044). Conclusion: Bicyclol could significantly relief elevation of ALT induced by the IFN treatment.
    Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology 09/2012; 26(2):114-6.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The dynamics of nitric oxide (NO) and peroxynitrite concentration changes during brain ischemia/reperfusion are poorly understood. In this paper, a NO-selective sensor was used to measure NO concentration changes in the rat brain hippocampus during global brain ischemia/reperfusion. Four-vessel occlusion model of transient global brain ischemia was used. Global cerebral ischemia was induced by occluding both common carotid arteries with artery nips (for 20 min) and reperfusion was induced by loosening the artery nips. Results showed that the changes of NO concentration during global brain ischemia/reperfusion could be divided into different stages. Together with the effects of O2 tension changes and NO synthase (NOS) on nitric oxide levels, we determined five stages in the NO concentration profile: (1) acute O2-limited decrease stage; (2) O2-limited steady stage; (3) neuronal NOS activation stage; (4) acute O2-recovery elevation stage; and (5) O2-recovery steady stage. In addition, a chemical reaction network model was constructed to simulate the dynamics of peroxynitrite during the reperfusion stage, and the effects of a change in the NO formation rate on the dynamics of peroxynitrite were investigated specifically. Results show the rate of NO formation has a great influence on peroxynitrite dynamics.
    Neurochemical Research 02/2008; 33(1):73-80. DOI:10.1007/s11064-007-9414-x · 2.59 Impact Factor
  • Source
    Chen Zhi · Liu Yong · Liu Ke-zhou · R. H. Dennin · Dou Jun · U Reinhard
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To determine the effective nucleotide sites of ribozymes against HCV, and obtain a highly effective, nontoxic and inexpensive antisense ribozyme specific for HCV. Methods: Two effective ribozymes, targeted to HCV 5’NC region and C region, were designed and synthesized. Eukaryotic expression vectors, pSV2-gpt. CD-SR (, containing either HCRZNC or HCRZC were constructued and transfected into MT-2 cells, which had been infected by HCV. Quantitative PCR and hydridization were used to determine the effect of inhibition of HCV by ribozymes. Results: HCRZNC and HCRZC suppressed the replication of HCV by 54.7% and 62.1%, respectively. Furthermore, when both ribozymes were cotransfected into cells, they suppressed replication by 78.8%. Conclusion: Two specific antisense ribozymes have strong inhibitory effects on the replication of HCV in cultured cells, and have better effect when used together.
    Journal of Zhejiang University - Science A: Applied Physics & Engineering 2(1):100-103. DOI:10.1007/BF02841185 · 0.88 Impact Factor